van Kesteren CA - Search Results

1

Uptake and proteolytic activation of prorenin by cultured human endothelial cells.

Admiraal PJ, van Kesteren CA, Danser AH, Derkx FH, Sluiter W, Schalekamp MA. Admiraal PJ, et al. Among authors: van kesteren ca. J Hypertens. 1999 May;17(5):621-9. doi: 10.1097/00004872-199917050-00005. J Hypertens. 1999. PMID: 10403605

2

Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding.

Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Danser AH, et al. Among authors: van kesteren ca. Circulation. 1997 Jul 1;96(1):220-6. doi: 10.1161/01.cir.96.1.220. Circulation. 1997. PMID: 9236437

3

Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells.

van Kesteren CA, Danser AH, Derkx FH, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA. van Kesteren CA, et al. Hypertension. 1997 Dec;30(6):1389-96. doi: 10.1161/01.hyp.30.6.1389. Hypertension. 1997. PMID: 9403558

4

Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II.

van Kesteren CA, Saris JJ, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. van Kesteren CA, et al. Cardiovasc Res. 1999 Jul;43(1):148-56. doi: 10.1016/s0008-6363(99)00057-7. Cardiovasc Res. 1999. PMID: 10536699

5

Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts.

van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. van Kesteren CA, et al. J Mol Cell Cardiol. 1997 Aug;29(8):2147-57. doi: 10.1006/jmcc.1997.0448. J Mol Cell Cardiol. 1997. PMID: 9281446

6

69th scientific sessions of the American Heart Association.

Danser AH, MaassenVanDenBrink A, van Kesteren CA. Danser AH, et al. Among authors: van kesteren ca. Expert Opin Investig Drugs. 1997 Jan;6(1):87-90. doi: 10.1517/13543784.6.1.87. Expert Opin Investig Drugs. 1997. PMID: 15989565

7

70th Scientific Sessions of the American Heart Association.

Jan Danser AH, van Kesteren CA, MaassenVanDenbrink A. Jan Danser AH, et al. Among authors: van kesteren ca. Expert Opin Investig Drugs. 1998 Jan;7(1):117-20. doi: 10.1517/13543784.7.1.117. Expert Opin Investig Drugs. 1998. PMID: 15991925

8

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH. van Kesteren Ch, et al. Invest New Drugs. 2003 May;21(2):225-41. doi: 10.1023/a:1023577514605. Invest New Drugs. 2003. PMID: 12889741 Review.

9

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604

10

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

van Kesteren Ch, de Vooght MM, López-Lázaro L, Mathôt RA, Schellens JH, Jimeno JM, Beijnen JH. van Kesteren Ch, et al. Anticancer Drugs. 2003 Aug;14(7):487-502. doi: 10.1097/00001813-200308000-00001. Anticancer Drugs. 2003. PMID: 12960733 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters